Document is current
Any future updates will be listed below
-
Authors
Hakim, Chady H. https://orcid.org/0000-0001-6865-050X
Kumar, Sandeep R. P.
Pérez-López, Dennis O.
Wasala, Nalinda B.
Zhang, Dong https://orcid.org/0000-0001-7297-5083
Yue, Yongping
Teixeira, James
Pan, Xiufang
Zhang, Keqing
Million, Emily D.
Nelson, Christopher E. https://orcid.org/0000-0002-8423-8854
Metzger, Samantha
Han, Jin
Louderman, Jacqueline A.
Schmidt, Florian https://orcid.org/0000-0002-6362-211X
Feng, Feng https://orcid.org/0000-0002-7299-9891
Grimm, Dirk https://orcid.org/0000-0001-6227-5665
Smith, Bruce F. https://orcid.org/0000-0001-8523-0355
Yao, Gang
Yang, N. Nora https://orcid.org/0000-0001-7245-8035
Gersbach, Charles A. https://orcid.org/0000-0003-1478-4013
Chen, Shi-jie
Herzog, Roland W. https://orcid.org/0000-0002-7213-998X
Duan, Dongsheng https://orcid.org/0000-0003-4109-1132
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32 GM008396)
University of Missouri Life Science Fellowship
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NS-90634)
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR-70517)
Parent Project Muscular Dystrophy (no number)
U.S. Department of Defense (MD150133)
Hope for Javier, Jackson Freel DMD Research Fund, Team Joseph, Charley’s Fund, Zubin’s Wish, Jett Foundation, Cure Duchenne, and Destroy Duchenne
- License Information
-
More Information
Article History
Received: 23 April 2021
Accepted: 21 October 2021
First Online: 24 November 2021
Competing interests
: D.D. is a member of the scientific advisory board for Solid Biosciences and equity holders of Solid Biosciences. The Duan lab has received research supports unrelated to this project from Solid Biosciences and Edgewise in the last three years. RWH has received research support from Luye R&D, royalty payments from Takeda Pharmaceuticals, and consulting fees from AGTC. None of these are related to this project. C.A.G., C.E.N., C.H.H., D.D., N.B.W., Y.Y. have filed patent applications related to genome editing for Duchenne muscular dystrophy. C.A.G. is an advisor to and receives research support from Sarepta Therapeutics, Inc., is a founder of M2X2 Therapeutics, Locus Biosciences, and Element Genomics, and is an advisor to Iveric Bio and Levo Therapeutics. D.G. is a co-founder and shareholder of AaviGen GmbH. The remaining authors declare no competing interests.
